Zobrazeno 1 - 10 of 14 pro vyhledávání: '"B. E. van den Borne"'
2
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer
Autor: Ernst-Jan M. Speel, Nils A. 't Hart, B. E. van den Borne, E. Van Der Heijden, Monika G. Looijen-Salamon, S. Riemersma, Lizza E.L. Hendriks, A. J. van der Wekken, Harry J.M. Groen, Ed Schuuring, Wim Timens, R. Pelgrim, A. Van Den Berg, Thijo J N Hiltermann, A.J. de Langen, N Werner, J. Staal-van den Brekel, Anne-Marie C. Dingemans, M. F. Mastik
Publikováno v: Clinical Cancer Research, 23(15), 4251-4258. AMER ASSOC CANCER RESEARCH
Europe PubMed Central
Clinical Cancer Research, 23(15), 4251-4258. American Association for Cancer Research Inc.
Clinical Cancer Research, 23, 4251-4258
Clinical Cancer Research, 23, 15, pp. 4251-4258
Van Der Wekken, A J, Pelgrim, R, T Hart, N, Werner, N, Mastik, M F, Hendriks, L, Van Der Heijden, E H F M, Looijen-Salamon, M, De Langen, A J, Staal-Van Den Brekel, J, Riemersma, S, Van Den Borne, B E, Speel, E J M, Dingemans, A M C, Hiltermann, T J N, Van Den Berg, A, Timens, W, Schuuring, E & Groen, H J M 2017, ' Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non–small cell lung cancer ', Clinical Cancer Research, vol. 23, no. 15, pp. 4251-4258 . https://doi.org/10.1158/1078-0432.CCR-16-1631
Purpose: ALK rearrangement detection using FISH is the standard test to identify patients with non–small cell lung carcinoma (NSCLC) eligible for treatment with ALK inhibitors. Recently, ALK protein expression in resectable NSCLC showed predictive
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::294301d2488887f96efb73185cf8e257
https://doi.org/10.1158/1078-0432.ccr-16-1631
Zobrazit plný text záznamu
3
A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)(aEuro)
Autor: Vincent van der Noort, Jacobus A. Burgers, Harry J.M. Groen, Jos A. Stigt, Idris Bahce, Egbert F. Smit, B. E. van den Borne, Bonne Biesma, Joachim G.J.V. Aerts, Gerarda J.M. Herder, Anne-Marie C. Dingemans, Andrew D. Vincent
Publikováno v: Dingemans, A M C, Groen, H J M, Herder, G J M, Stigt, J A, Smit, E F, Bahce, I, Burgers, J A, van den Borne, B E E M, Biesma, B, Vincent, A, van der Noort, V & Aerts, JG 2015, ' A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)(aEuro) ', Annals of Oncology, vol. 26, no. 11, pp. 2286-2293 . https://doi.org/10.1093/annonc/mdv370
Annals of Oncology, 26(11), 2286-2293. Elsevier Ltd.
Annals of Oncology, 26(11), 2286-2293. Oxford University Press
Background: Nitroglycerin ( NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia- inducible- factor ( HIF)- 1. A randomized phase II study has shown improved outcome when NTG patches were added to vinorelbine/ cisplatin in patients w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ce79aa82e47a39fa2e0aaa7862cfa29
https://doi.org/10.1093/annonc/mdv370
Zobrazit plný text záznamu
4
Quality of Life Following Stereotactic Ablative Radiation Therapy Versus Surgery for Early-Stage Lung Cancer: Results From the ROSEL Randomized Controlled Trial and a Systematic Review
Autor: Marinus A. Paul, Joachim Widder, George Rodrigues, Alexander V. Louie, Suresh Senan, E. van Werkhoven, Harry J.M. Groen, Berend J. Slotman, K. De Jaeger, David A. Palma, Andrew Warner, Egbert F. Smit, Hanbo Chen, B. E. van den Borne
Publikováno v: International Journal of Radiation Oncology Biology Physics, 96(2 Supplement), S10-S11. ELSEVIER SCIENCE INC
Louie, A V, Chen, H, Van Werkhoven, E, Smit, E, Palma, D A, Paul, M A, Warner, A, Widder, J, Groen, H J M, van Den Borne, B, De Jaeger, K, Rodrigues, G, Slotman, B J & Senan, S 2016, ' Quality of Life Following Stereotactic Ablative Radiation Therapy Versus Surgery for Early-Stage Lung Cancer: Results From the ROSEL Randomized Controlled Trial and a Systematic Review ', International Journal of Radiation Oncology Biology Physics, vol. 96, no. 2, pp. S10-S11 .
International Journal of Radiation Oncology Biology Physics, 96(2), S10-S11. Elsevier Inc.
Purpose/Objective(s)One of the purported advantages of stereotactic ablative radiation therapy (SABR) as an alternative treatment option to surgery for early-stage non-small cell lung cancer (ES-NSCLC) is health-related quality of life (HRQOL). The o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f1d5bcf216c2cfc382ba56ab38e69b
https://research.rug.nl/en/publications/0cf1800c-9f0d-4c8b-96f7-56f65f6c8e64
Zobrazit plný text záznamu
5
Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands
Autor: S.B. Oei, Jan Willem Coebergh, Maryska L.G. Janssen-Heijnen, Valery E.P.P. Lemmens, Bonne Biesma, B. E. van den Borne
Publikováno v: Critical Reviews in Oncology/Hematology, 62(2), 172-178. Elsevier Ireland Ltd
Management of small cell lung cancer (SCLC) among elderly is complex because of decreased organ functions and interactions with comorbidity. Since elderly patients are often excluded from clinical trials, little is known about the way they are treate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e17b0c137fdc1c61836865c681d419
https://hdl.handle.net/1765/36650
Zobrazit plný text záznamu
6
[Management of treatment refusal by a psychiatric patient with a life-threatening infectious form of pulmonary tuberculosis]
Autor: J B, Mertens, M J, Scherders, B E, van den Borne, F W, Smeenk
Publikováno v: Nederlands tijdschrift voor geneeskunde. 144(10)
A Somalian man aged 26 was admitted to a general hospital because of haemophthisis. A severe infectious and life threatening pulmonary tuberculosis was diagnosed. Thereafter, the patient denied having any disease, refused any therapy or diagnostic pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::02b85776d8e990636f0ae6d6eea46591
https://pubmed.ncbi.nlm.nih.gov/10726158
Zobrazit plný text záznamu
7
Combination cyclosporine and (hydroxy)chloroquine in rheumatoid arthritis
Autor: B A, Dijkmans, R B, Landewé, B E, van den Borne, F C, Breedveld
Publikováno v: Clinical and experimental rheumatology. 17(6 Suppl 18)
Antimalarials are attractive candidates for combination therapy. In vitro experiments have revealed a synergistic mode of action of cyclosporine and chloroquine which could not, however, be confirmed in a clinical trial.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2a27cad31a06e8b4707c261a35bf3bc8
https://pubmed.ncbi.nlm.nih.gov/10589367
Zobrazit plný text záznamu
8
Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss
Autor: B E, van den Borne, R B, Landewé, H S, Goei The, F C, Breedveld, B A, Dijkmans
Publikováno v: Rheumatology (Oxford, England), 38(3), 254-259. Oxford University Press
OBJECTIVES To investigate (1) whether the increase in serum creatinine observed during cyclosporin A (CsA) therapy was reversible in a group of patients with rheumatoid arthritis (RA) treated before the current guidelines for safe use in RA were deve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1127d0370a9533afacc68952a260f7ab
https://pubmed.ncbi.nlm.nih.gov/10325664
Zobrazit plný text záznamu
9
Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine
Autor: B E, van den Borne, R B, Landewé, H S, Goei The, J H, Rietveld, A H, Zwinderman, G A, Bruyn, F C, Breedveld, B A, Dijkmans
Publikováno v: The Journal of rheumatology. 25(8)
To investigate whether there is interaction between chloroquine and cyclosporine (CyA) at the level of efficacy and toxicity in patients with recent onset rheumatoid arthritis (RA).Eighty-eight patients with recent onset RA, who had shown a suboptima
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ecb984bfe84e48da8a5217476289a176
https://pubmed.ncbi.nlm.nih.gov/9712089
Zobrazit plný text záznamu
10
Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone
Autor: B A, Dijkmans, B E, van den Borne, R B, Landewe, A M, Miltenburg, C L, Verweij, F C, Breedveld
Publikováno v: The Journal of rheumatology. Supplement. 44
Combination therapy in rheumatoid arthritis (RA) with 2 or more disease modifying antirheumatic drugs (DMARD) is theoretically attractive if the drugs exert additional or even synergistic effects and have different toxicity patterns to avoid cumulati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7fd97a8cc26ff90592d9d0aaca2b8464
https://pubmed.ncbi.nlm.nih.gov/8833055
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje